More companies join the leaders, yet progress on AMR is slow

The 2020 AMR Benchmark evaluates 30 companies with a major stake in the anti-infectives space, including those with the largest R&D divisions, the largest market presence, and leading expertise in developing critically needed antibiotics and antifungals. These are among the last companies that remain invested in keeping such medicines and vaccines available and developing new ones.

Large R&D-based companies

86%
GSK
27 Projects in the pipeline
95 Products on the market
Score breakdown
36% Research & Development
13% Responsible Manufacturing
37% Appropriate Access & Stewardship
69%
Pfizer
8 Projects in the pipeline
190 Products on the market
Score breakdown
21% Research & Development
12% Responsible Manufacturing
36% Appropriate Access & Stewardship
68%
Johnson & Johnson
11 Projects in the pipeline
25 Products on the market
Score breakdown
22% Research & Development
13% Responsible Manufacturing
32% Appropriate Access & Stewardship
63%
Shionogi
8 Projects in the pipeline
7 Products on the market
Score breakdown
24% Research & Development
17% Responsible Manufacturing
21% Appropriate Access & Stewardship
54%
Novartis
1 Projects in the pipeline
152 Products on the market
Score breakdown
8% Research & Development
17% Responsible Manufacturing
29% Appropriate Access & Stewardship
52%
Otsuka
4 Projects in the pipeline
1 Products on the market
Score breakdown
21% Research & Development
9% Responsible Manufacturing
21% Appropriate Access & Stewardship
49%
Merck & Co, Inc
12 Projects in the pipeline
26 Products on the market
Score breakdown
19% Research & Development
12% Responsible Manufacturing
18% Appropriate Access & Stewardship
42%
Sanofi
6 Projects in the pipeline
102 Products on the market
Score breakdown
11% Research & Development
12% Responsible Manufacturing
19% Appropriate Access & Stewardship
GSKPfizerJohnson & JohnsonShionogiNovartisOtsukaMerck & Co, IncSanofi

Generic medicine manufacturers

70%
Cipla
N/A Projects in the pipeline
72 Products on the market
Score breakdown
N/A Research & Development
25% Responsible Manufacturing
45% Appropriate Access & Stewardship
63%
Teva
N/A Projects in the pipeline
202 Products on the market
Score breakdown
N/A Research & Development
26% Responsible Manufacturing
37% Appropriate Access & Stewardship
55%
Fresenius Kabi
N/A Projects in the pipeline
51 Products on the market
Score breakdown
N/A Research & Development
20% Responsible Manufacturing
35% Appropriate Access & Stewardship
53%
Abbott
N/A Projects in the pipeline
85 Products on the market
Score breakdown
N/A Research & Development
25% Responsible Manufacturing
28% Appropriate Access & Stewardship
53%
Mylan
N/A Projects in the pipeline
173 Products on the market
Score breakdown
N/A Research & Development
23% Responsible Manufacturing
30% Appropriate Access & Stewardship
31%
Aurobindo
N/A Projects in the pipeline
43 Products on the market
Score breakdown
N/A Research & Development
23% Responsible Manufacturing
9% Appropriate Access & Stewardship
14%
Alkem
N/A Projects in the pipeline
92 Products on the market
Score breakdown
N/A Research & Development
14% Responsible Manufacturing
0% Appropriate Access & Stewardship
11%
Sun Pharma
N/A Projects in the pipeline
90 Products on the market
Score breakdown
N/A Research & Development
11% Responsible Manufacturing
0% Appropriate Access & Stewardship
6%
Hainan Hailing
N/A Projects in the pipeline
47 Products on the market
Score breakdown
N/A Research & Development
6% Responsible Manufacturing
0% Appropriate Access & Stewardship
CiplaTevaFresenius KabiAbbottMylanAurobindoAlkemSun PharmaHainan Hailing

Pharmaceutical SMEs

80%
Entasis
4 Projects in the pipeline
N/A Products on the market
Score breakdown
80% Research & Development
N/A Responsible Manufacturing
N/A Appropriate Access & Stewardship
75%
Wockhardt
9 Projects in the pipeline
59 Products on the market
Score breakdown
75% Research & Development
N/A Responsible Manufacturing
N/A Appropriate Access & Stewardship
65%
Summit
3 Projects in the pipeline
N/A Products on the market
Score breakdown
65% Research & Development
N/A Responsible Manufacturing
N/A Appropriate Access & Stewardship
60%
Melinta
11 Projects in the pipeline
5 Products on the market
Score breakdown
60% Research & Development
N/A Responsible Manufacturing
N/A Appropriate Access & Stewardship
60%
Tetraphase
3 Projects in the pipeline
N/A Products on the market
Score breakdown
60% Research & Development
N/A Responsible Manufacturing
N/A Appropriate Access & Stewardship
50%
Amplyx
1 Projects in the pipeline
N/A Products on the market
Score breakdown
50% Research & Development
N/A Responsible Manufacturing
N/A Appropriate Access & Stewardship
45%
Debiopharm
4 Projects in the pipeline
N/A Products on the market
Score breakdown
45% Research & Development
N/A Responsible Manufacturing
N/A Appropriate Access & Stewardship
45%
Nabriva
7 Projects in the pipeline
N/A Products on the market
Score breakdown
45% Research & Development
N/A Responsible Manufacturing
N/A Appropriate Access & Stewardship
45%
Polyphor
3 Projects in the pipeline
N/A Products on the market
Score breakdown
45% Research & Development
N/A Responsible Manufacturing
N/A Appropriate Access & Stewardship
45%
Scynexis
5 Projects in the pipeline
N/A Products on the market
Score breakdown
45% Research & Development
N/A Responsible Manufacturing
N/A Appropriate Access & Stewardship
40%
Motif Bio
4 Projects in the pipeline
N/A Products on the market
Score breakdown
40% Research & Development
0% Responsible Manufacturing
0% Appropriate Access & Stewardship
30%
Achaogen
4 Projects in the pipeline
N/A Products on the market
Score breakdown
30% Research & Development
N/A Responsible Manufacturing
N/A Appropriate Access & Stewardship
30%
Cidara
3 Projects in the pipeline
N/A Products on the market
Score breakdown
30% Research & Development
N/A Responsible Manufacturing
N/A Appropriate Access & Stewardship
EntasisWockhardtSummitMelintaTetraphaseAmplyxDebiopharmNabrivaPolyphorScynexisMotif BioAchaogenCidara
Performance trends in 2020

More companies join the leaders, yet progress on AMR is slow

Company trends

Large R&D-based companies

GSK leads the group in 2020, followed closely by Pfizer and Johnson & Johnson. Shionogi has moved up, in front of Novartis and Otsuka. All companies in this group take diverse action to limit AMR. However, only a few continue to expand efforts to safeguard this critical area of modern medicine.

Learn more

Generic medicine manufacturers

Cipla, Teva and Fresenius Kabi take the lead in this group in 2020. All three are implementing policies that will help ensure antibacterial and antifungal medicines are promoted responsibly. Against a backdrop of greater disclosure, the leaders in this group are reported as taking additional steps against AMR compared to 2018.

Learn more

Pharmaceutical SMEs

Entasis leads in 2020, followed closely by Wockhardt. Three leaders stand out for targeting bacteria in the highest threat category defined by WHO and the CDC, and for supporting late-stage projects with plans to ensure better access and good stewardship soon after launch. Transparency in this group has improved since 2018.

Learn more

Explore the results

Research & Development

Read what the 2020 AMR Benchmark found when it analysed the R&D pipelines of eight large research-based companies and 13 pharmaceutical SMEs. It has mapped their medicine and vaccine projects targeting priority bacterial and fungal pathogens.

Learn more

Responsible Manufacturing

Read the results of the 2020 AMR Benchmark analysis into how eight large research-based companies and nine generic medicine manufacturers aim to minimise the risk that antibacterial discharge released from factories contributes to AMR.

Learn more

Appropriate Access & Stewardship

Read the findings from the 2020 AMR Benchmark on access strategies for antibacterial and antifungal products in LMICs from eight large research-based companies and nine generic medicine manufacturers, as well as stewardship initiatives.

Learn more

Back to top |